Automated image analysis for quantification of filamentous bacteria

BMC Microbiology

Volumn 15, Issue 1, 2015, Pages

  Fredborg, Marlene ^a,d   Rosenvinge, Flemming S ^b   Spillum, Erik ^c   Kroghsbo, Stine ^c   Wang, Mikala ^d   Sondergaard, Teis E ^e  

^a AARHUS UNIVERSITY   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

^c PHILIPS HEALTHCARE   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY   (Denmark)

Author keywords

Antibiotic induced filamentation; Cell elongation; Digital microscopy; Escherichia coli; Morphology; Time lapse imaging

Indexed keywords

AZTREONAM; BETA LACTAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBENICILLIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN; ANTIINFECTIVE AGENT;

ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; AUTOMATION; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIAL STRUCTURES; CELL SIZE; CONTROLLED STUDY; DIGITAL IMAGING; ESCHERICHIA COLI; IMAGE ANALYSIS; IMAGING SYSTEM; KINETICS; MICROBIOLOGICAL EXAMINATION; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MORPHOLOGICAL ADAPTATION; MULTIDRUG RESISTANCE; NONHUMAN; RAPID TEST; THREE DIMENSIONAL IMAGING; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; PROCEDURES; ULTRASTRUCTURE;

ALGORITHMS; ANTI-BACTERIAL AGENTS; AUTOMATION; BETA-LACTAMS; ESCHERICHIA COLI; IMAGING, THREE-DIMENSIONAL; MICROBIAL SENSITIVITY TESTS;

EID: 84946107178     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-015-0583-5     Document Type: Article

References (25)

1. Cabeen MT, Jacobs-Wagner C. Bacterial cell shape. Nat Rev Micro. 2005;3:601-10.
2. Periti P, Mazzei T. New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Int J Antimicrob Agents. 1999;12:97-105.
3. Hanberger H, Nilsson LE, Nilsson M, Maller R. Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis. 1991;10:927-34.
4. Justice SS, Hunstad DA, Cegelski L, Hultgren SJ. Morphological plasticity as a bacterial survival strategy. Nat Rev Micro. 2008;6:162-68.
5. Möller J, Luehmann T, Hall H, Vogel V. The race to the pole: how high-aspect ratio shape and heterogeneous environments limit phagocytosis of filamentous Escherichia coli bacteria by macrophages. Nano Lett. 2012;12:2901-5.
6. Justice SS, Hunstad DA, Seed PC, Hultgren SJ. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc Natl Acad Sci U S A. 2006;103:19884-89.
7. Möller J, Emge P, Vizcarra IA, Kollmannsberger P, Vogel V. Bacterial filamentation accelerates colonization of adhesive spots embedded in biopassive surfaces. New J Phys. 2013;15:125016.
8. Braga PC, Piatti G. Kinetics of filamentation of Escherichia coli induced by different Sub-MICs of ceftibuten at different times. Chemotherapy. 1993;39:272-77.
9. Walsh TR, Toleman MA. The emergence of pan-resistant gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother. 2012;67:1-3.
10. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis. 2001;32:1085-9.
11. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and β-lactamase activity in AmpC-and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol. 2004;42:269-75.
12. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206-12.
13. Fredborg M, Andersen KR, Jorgensen E, Droce A, Olesen T, Jensen BB, et al. Real-time optical antimicrobial susceptibility testing. J Clin Microbiol. 2013;51:2047-53.
14. Adinolfi LE, Bonventre PF. Enhanced phagocytosis, killing, and serum sensitivity of Escherichia coli and Staphylococcus aureus treated with sub-MICs of imipenem. Antimicrob Agents Chemother. 1988;32:1012-18.
15. Iida K, Hirata S, Nakamuta S, Koike M. Inhibition of cell division of Escherichia coli by a new synthetic penicillin, piperacillin. Antimicrob Agents Chemother. 1978;14:257-66.
16. Chung CC, Cheng IF, Chen HM, Kan HC, Yang WH, Chang HC. Screening of antibiotic susceptibility to beta-lactam-induced elongation of gram-negative bacteria based on dielectrophoresis. Anal Chem. 2012;84:3347-54.
17. Kjeldsen TS, Sommer MO, Olsen JE. Extended spectrum β-lactamase-producing Escherichia coli forms filaments as an initial response to cefotaxime treatment. BMC Microbiol. 2015;15:63.
18. Wayne P. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 17th Informational Supplement M100-S16.2007: 27-3
19. Renggli S, Keck W, Jenal U, Ritz D. Role of autofluorescence in flow cytometric analysis of Escherichia coli treated with bactericidal antibiotics. J Bacteriol. 2013;195:4067-73.
20. Yao Z, Kahne D, Kishony R. Distinct single-cell morphological dynamics under beta-lactam antibiotics. Mol Cell. 2012;48:705-12.
21. Sparbier K, Schubert S, Weller U, Boogen C, Kostrzewa M. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based functional assay for rapid detection of resistance against Beta-lactam antibiotics. J Clin Microbiol. 2012;50:927-37.
22. Sahare P, Moon A. Penicillin binding proteins, an insight into novel antibacterial drug target. Int J Eng Sci Res. 2014;5:13-23.
23. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam/bata-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5:365-83.
24. Noguchi H, Matsuhashi M, Mitsuhashi S. Comparative Studies of Penicillin-Binding Proteins in Pseudomonas aeruginosa and Escherichia coli. Eur J Biochem. 1979;100:41-9.
25. Rahme C, Butterfield JM, Nicasio AM, Lodise TP. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit? Diagn Microbiol Infect Dis. 2014;80:239-59.